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ABSTRACT
Background: Recent reports have identified distinct genomic patterns in 
ovarian carcinoma, including proliferative and mesenchymal-like groups, with worse 
outcome. The exact mechanisms driving the onset and progression of these tumors 
are still poorly understood. Additionally, researchers are concerned about the 
correct subtype stratification of the available cell line models, and the exploration 
of alternatives to monolayer culture. Identification of biomarkers to stratify cell 
lines, characterization of important processes as epithelial-mesenchymal transition 
(EMT), and the use of three-dimensional (3D) cultures as alternative models could 
be useful for cell line classification.
Methods and Results: In this work, we present a descriptive analysis of 16 
commonly used ovarian cancer cell lines. We have studied their morphology in 2- 
and 3D culture, and their response to cisplatin, observing in the majority of them an 
increased resistance in 3D. We have also performed an immunohistochemical analysis 
for proliferation marker Ki-67, and EMT related markers to establish phenotypes. 
Epithelial cells tend to show higher proliferative rates, and mesenchymal cells show 
an increase in EMT related markers, especially when cultured in 3D conditions.
Conclusions: We have stated the complex heterogeneity of ovarian cancer 
models, resembling primary tumors, agreeing with the argument that the cell line 
model for in vitro experiments must be carefully chosen. Our results also support that 
tridimensional culture could be a very helpful alternative in ovarian cancer research. 
Regarding EMT, a very important process for the development of this disease, some 
related biomarkers might be further characterized for their role in this disease 
development. 
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INTRODUCTION
The vast majority of malignant ovarian cancer cases 
are carcinomas, presumably originating from the Müllerian 
epithelium of the ovarian surface and the fallopian tube. 
The World Health Organization (WHO) classification 
distinguishes serous, mucinous, endometrioid and 
clear cell as the main histological subtypes. In the 
serous category, accounting for over 70% of all ovarian 
carcinomas (OC), the existence of two different diseases 
is now well established, low- and high-grade tumors, with 
distinct morphological and molecular characteristics [1]. 
The first step for dissemination involves detachment from 
the primary tumor and shedding to the abdominal cavity 
as individual cells or spheroids, both usually present in 
patients´ ascites [2, 3]. After this initial settlement on 
the peritoneal mesothelial lining, cells may activate 
mechanisms to start the metastatic outgrowth.
One of these mechanisms, epithelial to 
mesenchymal transition (EMT), is a developmental 
program that transiently disrupts cell-cell adhesion and 
converts epithelial cells into more migratory and invasive 
mesenchymal cells [4]. This process and its regulators 
have also been related to chemoresistance, emphasizing 
its relevance with respect to recurrence of disease [5, 6]. 
Noteworthy, different studies have pointed proliferative 
and mesenchymal-like groups, based on molecular 
features, and related them with a worse prognosis [7, 8]. 
The study of relevant pathways for cancer 
development has been facilitated by cell-based models. 
Immortalized OC cell lines have been used as an 
alternative to freshly isolated tumor cells since they have 
extended lifespan and their clonal nature reduces inter-
experimental variability. However, when cultured as a two-
dimensional (2D) monolayer, these cell lines demonstrate 
low functionality and an altered phenotype compared to 
primary cultures. There is an urgent need to characterize 
the existing models in order to use the most suitable ones 
for research. Additionally, alternatives to the classical 
monolayer culture such as three-dimensional (3D) cell 
culture that better represent tumor features, should be 
considered.
The main objective of this study was to establish 3D 
OC models, comparing them with bidimensional culture, 
and to characterize them for their growth, response to 
treatment, and expression of EMT markers.
RESULTS
Optimization and characterization of two-
dimension and spheroid growth OC cell lines
Two-dimensional morphology was analyzed by 
phase contrast imaging. We found two different patterns: 
round or epithelial (A2780, A2780CIS, OVCAR3, 
OAW28, PEA2, PEO23, TO14, PEO14, PEO1, PEO4 
and PEO6), and mesenchymal or fibroblast-like (PEA1, 
PEO16, OV56, SKOV3 and 59M) (Figure 1A). The 
doubling time ranges from 24 to 58 hours (Table 1), 
similar to previously reported data for ovarian cancer cell 
lines [9]. Mean values for epithelial and mesenchymal 
morphology cell lines are not statistically different (36.56 
± 10.26 vs 36.21 ± 8.67, respectively).
Spheroids individually created per well on ultra 
low attachment (ULA) plates (Corning) were quite 
reproducible, as previously described [10]. Using this 
method, we were able to detect three different patterns for 
3D growth of the cells. Some cell lines adopted a loose 
aggregate conformation (A2780, A2780CIS, OVCAR3, 
OAW28, PEA1, PEA2, PEO23, TO14), others had a 
more compact aggregate structure with an irregular, non-
spherical, and a less defined outer perimeter (PEO14, 
PEO1, PEO4 and PEO6), and a third group of cells, that 
adopted a tight spheroid structure, with very well defined 
perimeters under 3D culture (PEO16, OV56, SKOV3 
and 59M). Interestingly, the four cell lines that form 
compact spheroids share a mesenchymal or fibroblast-like 
morphology (Figure 1B). 
When cultured in monolayer, OC cell lines do not 
display any morphological features to indicate histology. 
However, on 3D, H&E stain revealed some features, 
including the presence of papillae in some of them, and 
existence of acellular central regions due to apoptosis or 
necrosis, as in tumor tissue (data not shown). Changes 
in size, measured in bright field microscopy, could be 
a surrogate marker of cell growth, but only in compact 
spheroids, so we used Ki-67 staining for evaluation of 
proliferation, that diminishes with time in compact spheres 
such as SKOV3, and remains constant in aggregates, as 
represented by PEO1 (Supplementary Figure 1).  
Cisplatin (CDDP) treatment
Monolayer cultures and spheroids were treated 
with increasing concentrations of CDDP for 72 h. Dose-
dependent reduction in cell viability was observed, 
but differences in drug response in 2D experiments 
are independent of histotype, phenotype or spheroid 
formation categories. Table 1 lists the IC50 values 
calculated for CDDP in ovarian cancer cell lines spheroids 
and monolayer cultures. Four groups of cell lines were 
established according to their IC50 values, taking IOSE 
cells as a reference (IC50 = 2 μM): sensible cells (IC50 < 
3 μM), partially sensitive cells (IC50 between 3 and 6 
μM), resistant cells (IC50 between 6 and 12 μM), and very 
resistant cells (IC50 > 12 μM). 
In all cell lines, independent of their 3D 
growth pattern, platinum response was evaluated 
by a luminescent assay (CellTiter-Glo) (Table 1). 
Additionally, CDDP sensitivity was evaluated by size 
and CAM staining in the four cell lines that are able 
to form compact spheroids (PEO16, OV56, SKOV3 
Oncotarget21895www.oncotarget.com
and 59M) obtaining comparable results (Figure 2). In 
this latter group, two cell lines maintain similar IC50 
values (fold change <2, PEO16 and 59M) whilst the 
other two show an increase when cultured in 3D (6.2 
and 4.0 fold for OV56 and SKOV3, respectively). 
The remaining group of aggregate forming cell lines, 
with the exception of two of them (A2780CIS and 
OVCAR3), did not reach the IC50 values when cultured 
on 3D conditions at the same concentration range set 
for 2D experiments (100 µM top concentration), and 
only one (A2780CIS), experimented a decrease in IC50 
(Table 1).
Immunohistochemical analysis
Ki-67 was employed to evaluate cell proliferation 
of cultures (Supplementary  Figure 1 and Table 1). The 
percentage of positive cells is similar comparing 2- and 3D 
globally (42.50 ± 26.39 vs 47.37 ± 6.70, respectively); no 
statistical differences were observed between 3D growing 
Figure 1: Morphological features of OC cell lines. Phase contrast images. (A) 2D-cultures show epithelial and fibroblast-like 
phenotypes; (B) 3D-cultured cells after 4 days formed 3 different structures: loose (top 2 rows) or compact (third row) aggregates and tight 
spheroids (bottom row). Scale bars = 250 μm.
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patterns, although the less proliferative seemed to be the 
compact aggregate type (52.5 ± 18.08 for loose aggregates, 
18.75 ± 5.15 for compact aggregates, and 59.12 ± 20.24 
for compact spheroids). Mean values became statistically 
different when we clustered the cells by morphological 
groups, increasing on 3D for the rounded cells (36.36 
± 28.64 vs 61.00 ± 36.49, p < 0.05), and decreasing for 
spindle subtype (56.00 ± 15.16 vs 17.40 ± 9.24, p < 0.05). 
Supplementary Table 1 includes detailed 
information regarding reported molecular alterations 
and putative histotype of the cell lines included in this 
study. We have found some discrepancies regarding P53 
expression. When it is completely absent or very highly 
expressed, it is widely used as a surrogate marker for TP53 
mutation, a ubiquitous molecular sign in high-grade serous 
ovarian carcinoma (HGSOC) [11]. Twelve of the cell lines 
showed abnormal expression of P53. The remaining cell 
lines, OVCAR3, OAW28, PEO14 and PEO23, presenting 
a normal expression pattern of the protein in our study, 
have been reported as TP53 mutated by different authors. 
PEO16, A2780 and 2780CIS showed an abnormal staining 
pattern; however, they are not reported as mutated on 
previous studies.  
Table 2 summarizes the results of the 
inmunohistochemistry (IHC) study on EMT-related 
markers. For the phenotypical classification of cell lines, 
we used the epithelial markers E-Cadherin (ECAD) and 
Pan-Cytokeratin (PANCK), and the mesenchymal markers 
N-Cadherin (NCAD) and Vimentin (VIM). Expression 
of these 4 markers was not mutually exclusive in the 
panel analyzed. With this algorithm, we classified four 
cell lines as purely epithelial (PEO4, PEO6, OAW28 y 
OVCAR3), and five as purely mesenchymal (PEO23, 
TO14, PEO16, A2780 y A2780CIS); the remaining cell 
lines were classified as intermediate. This phenotypical 
classification correlates with the morphology exhibited 
by the cells when cultured in monolayer in 12 of the 
lines; the remaining cell lines (PEO23, TO14, A2780 
and A2780CIS) exhibited a rounded morphology but 
expressed a mesenchymal immunohistotype. Interestingly, 
none of the compact aggregates expressed NCAD, and 
none of the cells forming compact spheroids expressed 
ECAD, and the latter remain in the mesenchymal category 
by this IHC classification (Supplementary Figure 2). 
Pooling pure and intermediate subtypes for statistical 
analysis, mesenchymal cells had a significant reduction 
on their doubling time compared to the epithelial group 
(41.07 ± 9.68 vs 31.83 ± 7.15, p = 0.04); no significant 
differences were observed on Ki-67 expression between 
2- or 3D culture (data not shown). 
Table 1: Main characteristics of ovarian cancer cell lines
Cell Line Origin Morphology Spheroid type
D.T. 72 h 
(h)
IC50 ± S.D. 
(μM)
Resist. IC50 3D ± S.D. 
(μM)
A2780 T Rounded LA 30.72 3.51 ± 0.69 PR NR
A2780CIS T Rounded LA 31.38 13.84 ± 0.93 VR 0.66 ± 0.10
OVCAR3 A Rounded LA 27.22 5.01 ± 0.28 PR 44.57 ± 0.71
PEO1 A Rounded CA 47.83 5.52 ± 0.42 PR NR
PEO4 A Rounded CA 33.34 16.11 ± 1.18 VR NR
PEO6 A Rounded CA 34.27 11.94 ± 2.74 VR NR
PEA2 A Rounded LA 44.13 20.80 ± 0.54 VR NR
PEO14 A Rounded CA 41.28 2.68 ± 0.11 S NR
PEO23 A Rounded LA 29.32 10.37 ± 0.30 R NR
TO14 T Rounded LA 24.21 10.43 ± 0.55 R NR
OAW28 A Rounded LA 58.45 4.59 ± 0.61 PR NR
PEA1 A Spindle LA 42.06 15.47 ± 2.31 VR NR
PEO16 A Spindle CS 33.76 5.48 ± 0.06 PR 7.21 ± 2.06
OV56 A Spindle CS 24.46 1.51 ± 0.22 S 9.34 ± 3.66
SKOV3 A Spindle CS 33.77 11.50 ± 1.47 R 46.03 ± 9.50
59M A Spindle CS 47 9.47 ± 0.78 R 11.83 ± 0.55
Origin: T = Tumor, A = Ascites; Spheroid morphology: LA = loose aggregate, CA = compact aggregate, CS = compact 
spheroid; D.T. 72 h = doubling time at 72 h; S.D. = Standard Deviation; Resistance grade: S = sensitive, PR = partially 
resistant, R = resistant, VR = very resistant; NR = not reached. 
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We also assessed the expression of master regulators 
of the EMT process in 2- and 3D culture conditions by 
IHC (Table 2). From the 16 cell lines analyzed on flat 
culture, markers were expressed as follows: Seven (44%) 
are positive for SNAIL, 2 (12%) are positive for SLUG 
and ZEB2, 3 (19%) for ZEB1, 9 (56%) for TWIST1, and 
13 (81%) for TWIST2. The expression is variable and we 
did not find any relation with the 3D growth patterns as 
aggregate or compact spheroids, response to platinum 
or proliferation, and the expression of the analyzed 
Figure 2: Dose-dependent sensitivity of Spheroids from 4 of the cell lines analyzed, with compact morphology. (A) CAM 
stained spheroids. Cells were treated with different CDDP concentrations. Images obtained with Celigo S cytometer; (B) Quantification of 
cell viability of the cells at different CDDP concentrations calculated with mean integrated CAM intensity values.
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markers. Globally, there is an increased expression of all 
the EMT markers analyzed in 3D. Specifically, splitting 
cells according to the epithelial or mesenchymal IHC 
phenotype, and comparing 2- and 3D culture, we observed 
an increased expression of SLUG and TWIST markers in 
the epithelial group and more expression of ZEB1, ZEB2, 
TWIST1 and TWIST2 in the mesenchymal type, when 
grown under low attachment conditions.
DISCUSSION
OC is traditionally divided into five main 
histological subtypes: serous (low- and high-grade), 
endometrioid, clear cell and mucinous. HGSOC accounts 
for more than 70% of cases, and is responsible for the 
majority of ovarian cancer related deaths [12]. Recently, 
large scale molecular profiles have confirmed the existence 
of different molecular subtypes in HGSOC (proliferative 
and mesenchymal-like), indicating that ovarian cancer is 
an heterogeneous disease, with different prognosis [7, 13]. 
Established cell lines are the most common model 
in cancer research, and their use has contributed to the 
understanding of cancer biology in the last decades, but 
they also have limitations. It is now widely accepted that 
some of the most frequently used ovarian cancer cell lines, 
including A2780, SKOV3 and OVCAR3, do not seem to be 
the most suitable models for the study of HGSOC [14–16].
We agree with other authors that the optimal cell line 
for in vitro studies must be carefully chosen, depending 
on numerous factors, including the endpoint of the 
study, growth characteristics, or histological or genomic 
background [10, 17]. 
2D culture is easy to handle and highly reproducible, 
but an objection to this model is that it does not totally 
mimic some properties of tumors, and sometimes fails 
to reproduce in vivo drug efficacy. More recently, 3D 
cell culture models, expected to bridge the gap between 
2D and animal models, are becoming more widely used 
in scientific research, including drug screening and 
new compounds development fields. Ovarian cancer 
has common tumor growth characteristics, such as 
a hypoxic environment, absent in traditional culture 
models. However, it also has some unique features, such 
as peritoneal spread as individual cells or aggregates. For 
all these reasons, 3D unattached culture could be a more 
representative model for these tumors.
Table 2: IHC of EMT biomarkers expression in cell lines, both in monolayer (2D) and 3D culture
Cell Line
EMT Markers Phenotype Classification
SNAIL SLUG ZEB1 ZEB2 TWIST1 TWIST2 ECAD PANCK NCAD VIM Phenotype
2D 3D 2D 3D 2D 3D 2D 3D 2D 3D 2D 3D 2D 3D 2D 3D 2D 3D 2D 3D 2D 3D
PEO4 – – – – – – + – + ++ + + R C C C A A A A E E
PEO6 – + – + – – – – + ++ – + R R C C A A A A E E
OAW28 + + – – – – – – – ++ + + R R C C A A A A E E
OVCAR3 + + – – – – – – + ++ + + R R C C A A A A E E
PEA2 – – – + – – – + + + + ++ R C C C A A R R IE IE
PEO1 – – – + – – – + + + + + R R C C A A R R IE IE
PEO14 + + – + – + – – – ++ + + R R C R A R R R IE I
PEA1 – + – + – + – + – ++ + ++ A A C R A A C C I IM
OV56 + + – + – + + + – ++ + + A A R C R R C C IM IM
SKOV3 – + – + + + – – – + + + A A C R R R C C IM IM
59M + – – – – + – – + ++ – – A A C R C C C C IM IM
PEO23 – + – + + + – + – ++ + ++ A A A A A A C C M M
TO14 – + – – + – – + – ++ + ++ A A A A A A C C M M
PEO16 – – – – – + – + + ++ + – A A A A C C C R M M
A2780 + + + – – + – + + ++ – + A A A A R R C C M M
A2780CIS + + + – – + – + + ++ + + A A A A R R C C M M
Phenotype: E = epithelial, IE = intermediate epithelial, I = intermediate, IM = intermediate mesenchymal, M = mesenchymal; 
A = absent, C = conserved, R = reduced, + = positive (moderate expression), ++ = positive (high expression), – = negative.
Oncotarget21899www.oncotarget.com
Previous work has been published on ovarian 
cancer spheroids culture using different methods 
[18–21]. However, these models that overcome some of 
the limitations of 2D, as the architectural growth of the 
tumor, are not yet fully attained. Reproducibility and easy 
management in the 2D setting are more complicated to 
perform on 3D. 
In this study, we characterized ovarian cancer 
spheroids from 16 commonly used cell lines, using ULA 
plates, in a highly uniform way, as previously described 
[10]. This method emulates more precisely the growth 
as aggregates (loose or compact) but also as solid 
tumors (compact spheroid), depending on the cell line. 
Interestingly, in this panel all cell lines with mesenchymal 
morphology formed compact spheroids. The compactation 
level on 3D had also been previously correlated to the 
spindle cell morphology by other authors [22].
Regarding compact spheroids experiments, 
assessment of cell number and days of incubation is 
crucial. An estimated diameter of 400 μm could be optimal 
to mimic the diffusion state in the tumor, which is about 
100 μm in depth for nutrients and oxygen, and 14 days 
as final time point was also effective to avoid excessive 
necrotic areas [23–25].  Proliferation of cells within the 
compact spheroids decreased over time but this effect is 
not necessarily accompanied by a decrease in the spheroid 
volume, which can remain tight and intact but with no 
viable cells. Therefore, vital staining with CAM could be 
used as direct indicator of cellular health, and it can also 
be coupled to Hoechst and PI for a more precise analysis 
on spheroids viability [26, 27].
Differences in cellular response to platinum were 
determined to be cell line specific. This can be explained 
because every cell line was established at a different 
treatment time-points: before or after first line, on different 
relapse states, or even after alternative chemotherapy 
regimes. In this study, 2- and 3D comparison in the 
compact spheroids group, show two cell lines that retain 
similar IC50 values, and other two that experiment an 
increase. The same behavior was seen for the aggregate 3D 
group where, with the exception of one cell line, all had an 
increase in the IC50 values. Moreover, most of them do not 
even reach this value under the same CDDP concentration 
range tested on 2D. These results are in agreement with 
the reported by other authors, supporting that cells tend to 
be more resistant to treatment when growing on 3D [28]. 
In advanced ovarian cancer, a high percentage of patients 
will develop ascites, and most of them will finally relapse, 
experiencing an increase in platinum resistance with 
recurrence. Under this scenario, and taking into account our 
results regarding the increased resistance observed in 3D 
culture, it could be worth considering unattached growth 
not only for compact spheroids but also for aggregates, to 
characterize resistance mechanisms in OC, as suggested by 
other authors [29]. The combination of a very reproducible 
approach for 3D culture, with reproducible single spheroids 
or aggregates per well, combined with a semi-automated 
quantification system as Celigo, could be a suitable model 
for ovarian cancer resistance research. This methodology 
allows the measurement of different culture features other 
than growth, such as migration, invasion or cell cycle 
progression, turning it into a very attractive approach 
[27, 30–32]. 
P53 pathway is disrupted in the majority of human 
cancers, mainly through mutation or deletion of TP53 
itself, and these situations have been associated with 
poor prognosis and chemoresistance in different types 
of tumors [33, 34]. In ovarian cancer, P53 is a useful 
marker to distinguish between HGSOC, mutated in 96% 
of the cases [35], and low-grade serous ovarian carcinoma 
(LGSOC), were mutations are very rare [1, 36]. In this 
study, we have detected an abnormal expression of P53 by 
immunohistochemical analysis in 12 out of 16 cell lines, 
which has been suggested to be a surrogate marker for 
TP53 mutation status [37]. However, we found discordant 
results in other 4 cell lines regarding their reported 
mutations on literature. These results are in agreement 
with the observation that P53 IHC accuracy is not perfect, 
and a combination of different markers might be used in 
order to better classify available cell lines [15, 17, 38]. 
We have also evaluated Ki-67 proliferation activity, 
which revealed a similar proliferation rate in 2- and 3D 
culture, although it has been shown to decrease in other 
reports [39]. Interestingly, if we split the sample by 
morphology, rounded cells increase their proliferation on 
3D meanwhile the spindle ones decrease it. 
During ovarian cancer progression, both EMT and 
the reverse process, mesenchymal-epithelial transition 
(MET) occur in a dynamic way, and a related phenotype 
has been pointed to have a more aggressive behavior 
[35, 40]. We have analyzed a selected panel of EMT 
markers, and we have observed co-expression of epithelial 
and mesenchymal markers, supporting the complexity 
and the dynamism of the process. This plasticity has 
been previously reported in ovarian cancer, particularly 
in HGSOC, were the balance between the epithelial and 
mesenchymal phenotypes is complex [4]. We also observed 
co-expression of different EMT regulators, grouped 
differently depending on the phenotypic background but 
we were not able to discriminate CDDP response rates 
regarding mesenchymal or epithelial features, probably 
because EMT is not the only process implicated in 
resistance mechanisms to platinum therapy, as previously 
reported [41]. Another explanation could be that we have 
only used a discrete set of EMT regulators, supported by 
the fact that the Cancer Genome Atlas Research Network 
pointed the mesenchymal subtype as one of the groups 
with a worse outcome. More research in the field should 
be done to identify related biomarkers [35, 40].
In most cell lines, there is an increased expression of 
master EMT regulators in 3D models comparing with 2D. 
Other authors have described changes in EMT regulators 
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between 2 and 3D ovarian cancer models and this could be 
in agreement with the role of the EMT process in disease 
dissemination, when the cells are growing unattached, like 
the ascitic cells in the abdominal cavity, before seeding the 
peritoneum [42]. Therefore, 3D culture could be a more 
suitable model for the study of EMT and related processes 
to further characterize the role of this mechanism in OC, 
and to identify additional biomarkers of aggressiveness. 
MATERIALS AND METHODS
2- and 3D culture conditions
Ovarian cancer cell lines were obtained from the 
European Collection of Authenticated Cell Cultures 
(ECACC), and cultured based on the guidelines of the 
repository. Cells were regularly tested for mycoplasma 
infection and discontinued after 15 consecutive passages. 
Some of these lines were established from the same patient 
during the course of disease, and had received different 
treatment schemes prior to their establishment: PEA1/
PEA2, PEO1/PEO4/PEO6 and PEO14/PEO23/T014 [43]. 
The cells were maintained in Roswell Park Memorial 
Institute (RPMI) or Dulbecco’s Modified Eagle Medium 
(DMEM) (Lonza, Basel, Switzerland) supplemented with 
10% Fetal Bovine Serum (FBS) and 100 U/ml penicillin–
streptomycin (Sigma-Aldrich, MO, USA). Immortalized 
Ovarian Surface Epithelium (IOSE) cells were obtained 
from the Canadian OvCaRe Cell Bank and grown in a 
combination of 199 and MCDB105 (1:1) media (Sigma-
Aldrich) with 5% FBS and 50 µg/ml gentamicin.  All cells 
were incubated at 37° C in a 5% CO2 incubator. Spheroids 
were cultured using ULA plates (Corning, NY, USA) as 
previously described [10], for up to 14 days. 
Cell proliferation
For monolayer experiments, cells were seeded at a 
density of 6 × 103 cells per well in 96-well plates (MW96). 
Cellular confluence was measured at different time points 
(0, 24, 48, 72 and 96 h). For 3D experiments, cells were 
seed at a variable density, set before for each cell line 
(from 500 to 10000 cells per well) in ULA plates. Growth 
was tracked measuring spheroid diameter at days 4, 7, 10 
and 14. Image acquisition and analysis were performed 
with Celigo S plate cytometer (Nexcelom, MA, USA). 
CDDP effects on ovarian cancer cell lines
Monolayer culture experiments were carried out in 
a similar way as proliferation assays and 24 hours after 
seeding, cells were exposed to different concentrations of 
(CDDP) for 72 h. After this time, cellular confluence was 
measured with Celigo S and IC50 values were calculated 
using linear regression with GraphPad Prism 7 software 
(GraphPad Software, CA, USA). 
For 3D experiments, after 4 days of culture, 
spheroids were exposed to CDDP for 72 h. Cell viability 
was measured using CellTiter-Glo Luminescent assay 
(Promega, WI, USA). Additionally, in compact spheroids, 
cells were treated with a fluorescent staining solution 
containing calcein-AM (CAM) (BD Biosciences) to detect 
live cells, propidium iodide (PI) (Sigma-Aldrich) for dead 
cells and Hoechst 33342 (Sigma-Aldrich) to counterstain 
all nuclei. Mean CAM intensity values obtained by 
Celigo analysis were used to calculate IC50 by using linear 
regression.
Histological and immunohistochemical analysis
Histological studies were performed both in cell 
pellets from monolayer cultures and aggregates or 
spheroids. Cell pellets were collected, fixed with 70% 
ethanol for 24 h, and paraffin embedded. Spheroids were 
fixed in 4% paraformaldehyde solution, embedded in 4% 
noble agar (Sigma-Aldrich) and then paraffin embedded. 
Sections were stained with haematoxylin and eosin (H&E). 
We performed IHC for the markers described below. 
Briefly, four-μm sections were cut with a semiautomatic 
microtome HM3508 (MICROM), deparaffinized and 
rehydrated in water. Antigen retrieval was performed in a 
DAKO PT Link (Glostrup, Denmark). Peroxidase activity 
was blocked with Dako Protein block for 10 minutes 
(containing 0.25% casein in PBS), then incubated for 
30 minutes with primary antibodies, detected with Dako 
Envision Plus kit, and counterstained with haematoxylin. 
Antibodies used include: Ki-67 (#IS626), P53 (#IS616), 
ECAD (#IR059), PANCK (#IR053), VIM (#IR630), all 
from Dako; NCAD (#ab1221), Snail (#ab135708), Slug 
(#ab38551), Zeb1 (#ab180905), Twist (#ab50581), and 
Twist2 (#ab57997), all from Abcam (Cambridge, UK), 
and Zeb2 (#sc-48789) from Santa Cruz (TX, USA).
Evaluation of immunohistochemical stains was 
performed as follows: ECAD, NCAD, PANCK, and 
VIM membrane staining was evaluated as conserved (C), 
reduced (R) or absent (A); cytoplasmic immunostaining 
of Snail, Slug, Twist1 and Twist2, and nuclear expression 
of Zeb1 and Zeb2, was evaluated as positive (moderate or 
high, when there is possibility of discriminate categories) 
or negative. P53 and Ki-67 were analyzed as a percentage, 
for ki-67 as continuous value of positive stained nuclei, 
and for P53 as two categories: aberrant expression (less 
than 10% or more than 60% positive nuclei), and normal 
expression (ranging from 11% to 59%), as previously 
described [33, 44, 45].
Phenotypical classification of the cell lines was 
done according to the expression of epithelial (ECAD/
PANCK) and mesenchymal (VIM/NCAD) markers. Cells 
were classified as purely epithelial or mesenchymal when 
they only expressed epithelial or mesenchymal markers; 
intermediate phenotypes were established when co-
expression of both groups of markers was observed.
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Statistical analysis
Results are representative of at least three 
independent experiments in triplicate to sextuplicate, 
and are represented as mean ± standard deviation (SD), 
except 3D experiments which were performed once with 6 
replicates for each condition. Chi-Square test and Fischer’s 
exact test (2-sided) were performed for comparisons, and 
these were considered significant when p-values < 0.05. 
Graphs and statistical analysis were performed using 
Microsoft Office Excel (Microsoft, WA, USA), SPSS 
version 15.0 (IBM Corporation, NY, USA), and GraphPad 
Prism 7 (GraphPad Software).
CONCLUSIONS
Spheroids show different features compared with 2D 
culture. Particularly in OC, epithelial ovarian cancer cells 
growing as spheroids are frequently detected in the ascites 
of the patients. We have successfully used a reproducible 
technique to obtain uniform ovarian cancer spheroids over 
16 established cell lines, and characterized their growth, 
proliferation, and drug response. Compelling evidence has 
suggested the critical role of EMT in cancer development 
and progression, but their regulation mechanisms need 
to be further characterized. We propose the use of 3D 
models for this purpose that, with optimal instrumentation 
and computational coupled resources, could represent a 
promising model for high throughput studies.
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